Europe Point Of Care TB And Drug-resistant TB Testing Market Size, Share & Trends Analysis Report By Test (Molecular Diagnostics, Immunoassays), By End Use (Clinics & Hospitals), By Country, And Segment Forecasts, 2024 - 2030
Europe Point Of Care TB And Drug-resistant TB Testing Market Growth & Trends
The Europe point of care TB and drug-resistant TB testing market size is expected to reach USD 161.05 million by 2030 and is projected to grow at a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by several factors, notably the high prevalence of tuberculosis (TB) and increasing cases of drug-resistant strains. Despite a 25% reduction in TB deaths by 2022, as reported by the Global Tuberculosis Report, progress was significantly impacted by COVID-19. The WHO European Region saw a gain reversal due to pandemic-related disruptions, with TB incidence rates remaining above pre-pandemic levels in 2022. This ongoing challenge underscores the need for practical, rapid diagnostic solutions to manage TB and DR-TB effectively.
Government and regulatory support further drive the market’s expansion. The European Union’s strategic initiatives, such as the Action Plan on Antimicrobial Resistance (AMR) and the WHO’s Regional Platform to End TB in Eastern Europe, emphasize the importance of enhancing diagnostic capabilities and treatment strategies for TB and drug-resistant strains. These initiatives aim to address the setbacks caused by COVID-19 and improve TB outcomes through increased investment in point of care (PoC) technologies. Additionally, the certification of advanced diagnostic tools like QuantiFERON-TB Gold Plus under the EU’s new In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746 highlights the regulatory push for higher standards in TB diagnostics, contributing to market growth.
Technological advancements play a crucial role in market expansion. Recent developments in molecular diagnostics, including rapid PCR assays and next-generation sequencing (NGS), have significantly improved the accuracy and speed of TB detection. These innovations enable high-throughput testing and precise identification of drug-resistant strains, addressing the urgent need for timely diagnosis and treatment.
Europe Point Of Care TB And Drug-resistant TB Testing Market Report Highlights
- Based on test, the immunoassays segment dominated the market with a substantial share of 34.9% in 2023, due to its rapid results and ease of use.
- In 2023, the clinics and hospitals segment dominated the market with the largest share of 48.1%.
- Clinics and hospitals are primary settings for TB diagnosis and management due to their capacity to offer comprehensive diagnostic and treatment services.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Test
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Test
- 2.2.2. End Use
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Europe PoC TB and Drug-Resistant TB Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. High TB Incidence and Drug Resistance Rates
- 3.2.1.2. Government and Regulatory Support
- 3.2.1.3. Technological Advancements
- 3.2.2. Market restraint analysis
- 3.2.2.1. High Costs of Advanced Diagnostics
- 3.2.2.2. Regulatory and Compliance Challenges
- 3.3. Europe PoC TB and Drug-Resistant TB Testing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Europe PoC TB and Drug-Resistant TB Testing Market: Test Estimates & Trend Analysis
- 4.1. Europe PoC TB and Drug-Resistant TB Testing Market: Test Dashboard
- 4.2. Europe PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
- 4.3. Europe PoC TB and Drug-Resistant TB Testing Market by Test, Revenue
- 4.4. Molecular Diagnostics
- 4.4.1. Molecular Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Immunoassays
- 4.5.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Culture-based Tests
- 4.6.1. Culture-based Tests market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Serological Tests
- 4.7.1. Serological Tests market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Others
- 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Europe PoC TB and Drug-Resistant TB Testing Market: End Use Estimates & Trend Analysis
- 5.1. Europe PoC TB and Drug-Resistant TB Testing Market: End Use Dashboard
- 5.2. Europe PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
- 5.3. Europe PoC TB and Drug-Resistant TB Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
- 5.4. Clinics and Hospitals
- 5.4.1. Clinics and Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Diagnostic Laboratories
- 5.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Europe PoC TB and Drug-Resistant TB Testing Market: Regional Estimates & Trend Analysis by Test, and End Use
- 6.1. Regional Dashboard
- 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.3. Europe
- 6.3.1. UK
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework/ reimbursement structure
- 6.3.1.3. Competitive scenario
- 6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Germany
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. France
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Regulatory framework/ reimbursement structure
- 6.3.3.3. Competitive scenario
- 6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.4. Italy
- 6.3.4.1. Key country dynamics
- 6.3.4.2. Regulatory framework/ reimbursement structure
- 6.3.4.3. Competitive scenario
- 6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.5. Spain
- 6.3.5.1. Key country dynamics
- 6.3.5.2. Regulatory framework/ reimbursement structure
- 6.3.5.3. Competitive scenario
- 6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.6. Norway
- 6.3.6.1. Key country dynamics
- 6.3.6.2. Regulatory framework/ reimbursement structure
- 6.3.6.3. Competitive scenario
- 6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.7. Sweden
- 6.3.7.1. Key country dynamics
- 6.3.7.2. Regulatory framework/ reimbursement structure
- 6.3.7.3. Competitive scenario
- 6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.8. Denmark
- 6.3.8.1. Key country dynamics
- 6.3.8.2. Regulatory framework/ reimbursement structure
- 6.3.8.3. Competitive scenario
- 6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.9. Russia
- 6.3.9.1. Key country dynamics
- 6.3.9.2. Regulatory framework/ reimbursement structure
- 6.3.9.3. Competitive scenario
- 6.3.9.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.10. Armenia
- 6.3.10.1. Key country dynamics
- 6.3.10.2. Regulatory framework/ reimbursement structure
- 6.3.10.3. Competitive scenario
- 6.3.10.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.11. Azerbaijan
- 6.3.11.1. Key country dynamics
- 6.3.11.2. Regulatory framework/ reimbursement structure
- 6.3.11.3. Competitive scenario
- 6.3.11.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.12. Belarus
- 6.3.12.1. Key country dynamics
- 6.3.12.2. Regulatory framework/ reimbursement structure
- 6.3.12.3. Competitive scenario
- 6.3.12.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.13. Kazakhstan
- 6.3.13.1. Key country dynamics
- 6.3.13.2. Regulatory framework/ reimbursement structure
- 6.3.13.3. Competitive scenario
- 6.3.13.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.14. Rest of Europe
- 6.3.14.1. Key country dynamics
- 6.3.14.2. Regulatory framework/ reimbursement structure
- 6.3.14.3. Competitive scenario
- 6.3.14.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Company/Competition Categorization
- 7.2. Vendor Landscape
- 7.2.1. List of key distributors and channel partners
- 7.2.2. Key company market share analysis, 2023
- 7.2.3. Cepheid (Danaher Corporation)
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Molbio Diagnostics
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Abbott Laboratories
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. BD (Becton, Dickinson and Company)
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. Roche Diagnostics
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Qiagen
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. Lucira Health
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives
- 7.2.10. BioMérieux
- 7.2.10.1. Company overview
- 7.2.10.2. Financial performance
- 7.2.10.3. Product benchmarking
- 7.2.10.4. Strategic initiatives
- 7.2.11. Thermo Fisher Scientific
- 7.2.11.1. Company overview
- 7.2.11.2. Financial performance
- 7.2.11.3. Product benchmarking
- 7.2.11.4. Strategic initiatives
- 7.2.12. Fujifilm (Fujifilm Healthcare)
- 7.2.12.1. Company overview
- 7.2.12.2. Financial performance
- 7.2.12.3. Product benchmarking
- 7.2.12.4. Strategic initiatives
- 7.2.13. MedMira
- 7.2.13.1. Company overview
- 7.2.13.2. Financial performance
- 7.2.13.3. Product benchmarking
- 7.2.13.4. Strategic initiatives
- 7.2.14. SD Biosensor
- 7.2.14.1. Company overview
- 7.2.14.2. Financial performance
- 7.2.14.3. Product benchmarking
- 7.2.14.4. Strategic initiatives
- 7.2.15. Trivitron Healthcare
- 7.2.15.1. Company overview
- 7.2.15.2. Financial performance
- 7.2.15.3. Product benchmarking
- 7.2.15.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook